Bionomics Limited Files Patent Applications for Cancer Drug Target BNO69

Bionomics Limited, an Australian-based biotechnology company, has taken a significant step in advancing its proprietary cancer drug target, BNO69, by filing further patent applications in key markets, including the United States. Building on recent scientific breakthroughs, BNO69 has emerged as a promising target for inhibiting angiogenesis, a key factor in the growth of solid cancers. The company's research has demonstrated the potential of BNO69 in directly targeting cancer cells and has shown promising results in animal studies, with tumour size reductions of up to 94% observed.

Key Takeaways:

• Bionomics Limited has filed patent applications for BNO69, a proprietary cancer drug target, in key markets, including the United States.
• BNO69 has been identified as a target for inhibiting angiogenesis, a key factor in the growth of solid cancers, through publications in prestigious scientific journals, including Proceedings of the National Academy of Sciences USA (PNAS) and Physiological Genomics.
• Recent findings indicate that BNO69 and molecules that silence its expression may have therapeutic utility in directly targeting cancer cells, with cell-based assays demonstrating tumorigenic behaviour curtailment in a number of tumour cell types, including breast and colon cancer.
• Animal studies have shown that molecules which silence BNO69 have a profound effect on tumour growth, with observed tumour size reductions of up to 94%, significantly smaller tumours (over 75%) compared to untreated cells.
• Bionomics is leveraging its gene discoveries in epilepsy with its proprietary ionX(r) discovery platform for the development of new treatments for CNS disorders, including anxiety.
• The company is also utilizing the Angene(tm) platform for the discovery of drugs for the treatment of cancer and seeking to generate exponential growth through acquisition.

Statistics:

• Bionomics has observed tumour size reductions of up to 94% in repeat studies.
• Cancer cells treated with BNO69 gene-silencing molecules showed a significantly reduced capacity in forming solid tumours in mice.
• Tumours arising from cells treated with BNO69 silencing molecules were over 75% smaller compared to tumours arising from untreated cells.
• Bionomics has confirmed its data in repeat studies, with tumour size reductions as high as 94% observed.

Sources:

• Bionomics Limited official announcement.
• Proceedings of the National Academy of Sciences USA (PNAS).
• Physiological Genomics.
• Bionomics Limited press release.